| 1 |
35600474 | Differential Inhibition of Platelet Reactivity by Dual Therapy With Aspirin and Low-Dose Rivaroxaban in Peripheral Arterial Disease: A Pilot Study. | 2022 |
1 |
| 2 |
34323663 | Rivaroxaban protects from the oxysterol-induced damage and inflammatory activation of the vascular endothelium. | 2021 Oct 2 |
1 |
| 3 |
31215111 | Rivaroxaban pharmacodynamics in healthy volunteers evaluated with thrombin generation and the active protein C system: Modeling and assessing interindividual variability. | 2019 Oct |
2 |
| 4 |
26757012 | An in-vitro evaluation of direct thrombin inhibitor and factor Xa inhibitor on tissue factor-induced thrombin generation and platelet aggregation: a comparison of dabigatran and rivaroxaban. | 2016 Dec |
3 |
| 5 |
23463187 | Tissue factor-mediated activation of the prothrombin complex concentrate (PCC) is differently inhibited by dabigatran, rivaroxaban, and apixaban: potential clinical implication. | 2013 Nov-Dec |
1 |
| 6 |
20589316 | Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: comparison with direct inhibitors of factor VIIa, XIa and thrombin. | 2010 Aug |
1 |